2 Jan 2018 07:00
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE
COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION
IS CONSIDERED TO BE IN THE PUBLIC DOMAIN
Mereo BioPharma Group plc
("Mereo" or the "Company" or the "Group")
£10 million credit facility drawdown and issue of warrants
Second and final tranche of credit facility drawn
London, January 2, 2018 - Mereo BioPharma Group plc (AIM: MPH), a multi-asset biopharmaceutical company focused on the acquisition, development and commercialisation of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases, is pleased to announce that on December 29, 2017 it drew down the second and final £10 million tranche of the credit facility set up in August 2017 with Silicon Valley Bank and Kreos Capital (the "lenders").
With its existing cash position, together with this drawdown of the remainder of its credit facility, Mereo has a strong balance sheet with sufficient cash resources to fund its key clinical programmes.
The terms are as previously disclosed and are typical for facilities of this type and include an interest only period to September 30, 2018, a thirty-month capital and interest repayment period thereafter, a competitive high single digit headline interest rate and customary security over assets of the Group.
In connection with the drawdown, on December 29, 2017 the Company issued warrants giving the lenders the right to subscribe for 333,334 shares at a price of 330 pence per share, currently equivalent to approximately 0.5% of the issued share capital of the Company. These warrants will be capable of exercise until August 21, 2027.
Ends
For Further Enquiries:
Mereo BioPharma Group plc | +44 (0)333 023 7319 |
Denise Scots-Knight, Chief Executive Officer |
|
Richard Jones, Chief Financial Officer |
|
|
|
Nominated Adviser and Joint Broker Cantor Fitzgerald Europe | +44 (0)20 7894 7000 |
Phil Davies |
|
Will Goode |
|
|
|
Joint Broker RBC Capital Markets | +44 (0)20 7653 4000 |
Rupert Walford |
|
Laura White |
|
|
|
Public Relations Adviser to Mereo FTI Consulting | +44 (0)20 3727 1000 |
Ben Atwell |
|
Simon Conway |
|
Brett Pollard |
|
|
|
US Public Relations Advisor to Mereo Burns McClellan | +01 (0) 212 213 0006 |
Lisa Burns |
|
Steven Klass |
|
About Mereo
Mereo is a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. The portfolio consists of four clinical-stage product candidates, each of which were acquired from large pharmaceutical companies: BPS-804 for the treatment of osteogenesis imperfecta, or OI; AZD-9668 for the treatment of severe alpha-1 antitrypsin deficiency, or AATD; BGS-649 for the treatment of hypogonadotropic hypogonadism, or HH, in obese men; and BCT-197 for the treatment of acute exacerbations of chronic obstructive pulmonary disease, or AECOPD. Each of the Company's product candidates has generated positive clinical data for the target indication or in a related disease. The Company's strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. Since inception the Company has commenced large, randomized, placebo-controlled Phase 2 clinical trials for three of the product candidates and announced positive top-line results from its Phase 2 clinical trial of BCT-197 as an acute therapy for patients with acute exacerbations of chronic obstructive pulmonary disease in December 2017. The Company intends to commence additional late-stage clinical trials in 2018.